A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer☆
Introduction
There will be approximately 11,070 cases of invasive cervical cancer expected in the United States in 2008, with an estimated 3870 deaths [1]. In developing countries, cervical cancer is the leading cause of cancer-related mortality causing over 272,000 deaths in 2007 [2]. Between 1988 and 2001, there were 95,353 registered cases of cervical carcinoma in the Surveillance Epidemiology and End Results (SEER) database, of which approximately 55% were locally advanced disease diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IB2-IVA [3]. A new standard for the treatment of locally advanced cervical cancer was established in 1999 [4], [5]. The addition of weekly cisplatin at 40 mg/m2 for 6 weeks in combination with radiation (RT) reduces the relative risk of death from cervical cancer by approximately 50% by decreasing local failure and distant metastases [6], [7], [8], [9], [10]. This combination was favored because Gynecologic Oncology Group (GOG) Protocol 120 showed it to be less toxic and as equally efficacious when compared with other combinations using hydroxyurea and/or 5-flourouracil (5-FU) [8]. Multimodality therapy is now the standard of care for locally advanced cervical carcinoma [11].
Topotecan acts synergistically with cisplatin and potentiates its cytotoxic activity against cancer cells. The mechanism is thought to occur through DNA repair inhibition [12]. The combination of these two agents was hypothesized to cause greater antitumor activity than might be expected from the additive effects of the two drugs. Clinical trials have since proven this hypothesis in patients with advanced or recurrent cervical cancer [13], [14]. Although more hematologically toxic, the combination does not appear to significantly reduce patient quality of life (QOL) when compared with cisplatin alone [15]. GOG Protocol 179 was the first randomized phase III trial to demonstrate a survival advantage for the combination of cisplatin and topotecan over cisplatin alone in recurrent or stage IVB cervical cancer [14]. Topotecan is also a radiosensitizing agent [16] and has been studied at various daily dosing regimens in patients with advanced cervical cancer receiving external beam RT and low-dose rate (LDR) brachytherapy [17], [18].
Based on these data, the objective of the present study was to assess the activity, feasibility and toxicity of adding weekly topotecan which is less marrow toxic than the previously studied daily schedules to cisplatin in previously untreated patients with primary, locally advanced (FIGO stage IB2 through IVA) carcinoma of the cervix receiving concurrent pelvic RT.
Section snippets
Materials and methods
The UCI Institutional Review Board approved the study before any patients were enrolled. All patients provided written informed consent meeting all federal, state and local requirements before receiving any protocol therapy.
Patients with primary, previously untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, Stage IB2, IIB, IIIB and IV-A whose disease was limited to the pelvis were eligible. Negative para-aortic
Results
Enrollment of eligible patients began in February 2004. The twelfth and final patient enrolled on August 3, 2007. The majority of patients enrolled were stage IIB (66%), had squamous cell (92%) and high grade (66%) histology. Clinical characteristics are listed in Table 1. Fifty-eight cycles of chemotherapy, median of 5 per patient, were administered during radiation therapy. Of the six patients in the first stage of accrual, 3 patients finished the prescribed therapy in over 8 weeks. The
Discussion
These results show that the addition of topotecan to standard dose cisplatin (40 mg/m2) and pelvic radiation is feasible at a dose of 2 mg/m2. While this was a pilot study of 12 patients, response data demonstrate a complete response rate of 91.7% (95% CI 55%–100%). With a median follow-up of 22 months, 83.3% of patients were without evidence of disease.
Hematologic toxicity was expected with this combination and lead to delays in therapy. One patient was able to complete 6 courses of
Conflict of interest
The authors have no conflicts of interest to declare.
Acknowledgment
This study was supported by Glaxo Smith Kline.
References (21)
The role of topotecan in the treatment of advanced cervical cancer
Gynecol. Oncol.
(2003)- et al.
Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix
Gynecol. Oncol.
(2002) - et al.
Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial
Gynecol. Oncol.
(2001) - et al.
Phase I study of topotecan and radiation therapy in advanced cervical cancer
Gynecol. Oncol.
(2002) - et al.
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials
Gynecol. Oncol.
(2007) - et al.
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
Gynecol. Oncol.
(2008) - et al.
Cancer statistics, 2008
CA Cancer J. Clin.
(2008) - et al.
Global cancer facts & figures 2007
(2007) - et al.
SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, patient and tumor characteristics
(2007) - The National Cancer Institute Clinical Announcement on Cervical Cancer. 1999 [cited; Available from:...
Cited by (15)
A phase i study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study
2012, Gynecologic OncologyCitation Excerpt :Since the design and conduct of this trial, three studies have been published which are relevant to our study and the future trials of chemoradiation. The first is a phase II feasibility trial of the same combination with pelvic radiation for locally advanced cervical cancer conducted at University of California at Irvine [23]. This trial of 12 patients delivered cisplatin 40 mg/m2 weekly followed by topotecan 2.0 mg/m2.
Exenteration as a primary treatment for locally advanced cervical cancer: Long-term results and prognostic factors
2011, American Journal of Obstetrics and GynecologyCitation Excerpt :Chemoradiation is also the recommended therapy for LACC, although its benefit compared with other therapies has not been confirmed.38,41 The addition of a second substance such as Topotecan improved response rates (92% cR) but raised toxicity in a small study (n = 12, median follow-up 22 months).42 Our department recruits patients supraregionally for exenterative surgery, and for this study, we included only those patients in whom a PE was actually carried out.
Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy
2011, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Nonetheless, outcomes for patients with advanced disease are still suboptimal, suggesting that treatment could be intensified for some patients. Preliminary clinical studies of combination chemotherapy given concurrently with RT have demonstrated promising disease control; however, the high rate of HT is a limiting factor (28–31). Finally, limiting CRT-associated BM injury incurred during definitive therapy may improve tolerance to subsequent chemotherapy given in the adjuvant or recurrent/metastatic setting.
Low-dose range of pelvic irradiation leads to acute hematological toxicity in early-stage cervical cancer with intermediate risk factors by postoperative intensity-modulated radiotherapy
2019, European Journal of Gynaecological OncologyNovel agents and treatment techniques to enhance radiotherapeutic outcomes in carcinoma of the uterine cervix
2016, Annals of Translational MedicineIn vitro chemoresponse analysis of cervical cancer patient specimens
2014, International Journal of Gynecological Cancer
- ☆
Presented at the 39th Annual Clinical Meeting of the Society of Gynecologic Oncologists, March 9–12, 2008, Tampa, FL. Supported by a grant from GlaxoSmithKine, Inc. The authors wish to thank Daniele Sumner and Anita Wallick for their assistance with data collection and manuscript preparation.